Agenus (AGEN) vs Fennec Pharmaceuticals (FENC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Agenus (AGEN) has outperformed Fennec Pharmaceuticals (FENC) over the past year, gaining 80.5% versus a gain of 14.8%. Over five years, FENC leads with a +16.5% price change compared with -92.6% for AGEN. Fennec Pharmaceuticals is the larger company by market cap ($375.6 million vs $346.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | FENC |
|---|---|---|
| Share price | $7.67 | $10.71 |
| Market cap | $346.39M | $375.57M |
| 1-day change | +1.72% | +0.75% |
| YTD return | +144.27% | +39.09% |
| 1-year return | +80.47% | +14.79% |
| 5-year return | -92.64% | +16.54% |
| P/E ratio (TTM) | 3.03 | — |
| Forward P/E | — | 11.30 |
| EPS (TTM) | $2.53 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $13.25 |
| 52-week low | $2.71 | $5.65 |
| Distance from 52-week high | -25.61% | -19.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +243.29% | +64.99% |
| Average volume | 4.26M | 191.88K |
| Shares outstanding | 45.16M | 35.07M |
| Employees | 81 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed FENC by 65.7 percentage points over the past year.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
AGEN vs FENC FAQ
Which is bigger, Agenus or Fennec Pharmaceuticals?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $375.57M compared with $346.39M for Agenus (AGEN).
Which stock has performed better over the past year, AGEN or FENC?
AGEN returned +80.47% over the past 12 months, compared with +14.79% for FENC (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Fennec Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.